1. In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa;K Young;BMC Microbiol,2019
2. Activity of Imipenem-Relebactam and Comparator Agents against Genetically Characterized Isolates of Carbapenem-Resistant Enterobacteriaceae;MC Canver;Antimicrob Agents Chemother,2019
3. RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections;J Motsch;Clin Infect Dis,2019
4. https://investors.merck.com/news/press-release-details/2019/Pivotal-RESTORE-IMI-2-Phase-3-Study-of-Mercks-RECARBRIO-imipenem-cilastatin-and-relebactam-in-Hospital-Acquired-and-Ventilator-Associated-Bacterial-Pneumonia-HABPVABP-Met-Primary-Endpoint/default.aspx
5. Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients;RP Veiga;Crit Care,2018